[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574685":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":35,"centralContacts":39,"locations":44,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Stakeholders",null,"physicians involved in the diagnosis and treatment decision for patients with early breast cancer (10 oncologists, 10 breast surgeons, and 10 breast radiologists specifically).",[13],"Other: Healthcare professionals",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients PDA group","Participants randomized in this group will receive via mail the final version of the PDA and a Qualtrics link with a battery of questionnaires",[18],"Other: Patients PDA group",{"label":20,"type":10,"description":21,"interventionNames":22},"Patients control group","Patients randomized in this group will receive only the online link with the battery of questionnaires.",[23],"Other: Patients control group",[25,29,32],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Healthcare professionals","healthcare professionals (HCPs) targeted, including team members: we will involve 30 physicians (who are involved in the process of care towards patients with early breast cancer (10 oncologists, 10 breast surgeon, and 10 breast radiologists specifically) for the semi-structured interviews",[9],{"type":6,"name":15,"description":30,"armGroupLabels":31,"otherNames":10},"Participants will receive via mail the final version of the PDA and a Qualtrics link with a battery of questionnaires",[15],{"type":6,"name":20,"description":33,"armGroupLabels":34,"otherNames":10},"Participants will receive only the online link with the battery of questionnaires",[20],[36],{"name":37,"affiliation":5,"role":38},"Gabriella Pravettoni","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":10,"email":43},"CONTACT","0039 02 57489731","gabriella.pravettoni@ieo.it",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":48,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":10},"RECRUITING","Milan","Italy","20141","IT",{"type":52,"coordinates":53},"Point",[54,55],9.18951,45.46427,{"lat":55,"lon":54},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100574685","a-new-tool-to-promote-patients-engagement-in-their-healthcare-process-100574685",false,"NCT06762496","A New Tool to Promote Patient's Engagement in Their Healthcare Process","Development and Testing of a Patient's Decision Aid for Early Breast Cancer: a New Tool to Promote Patient's Engagement in Their Healthcare Process","Inclusion Criteria:\n\n* be 18 or older;\n* have received\u002Freceive diagnosis of resectable breast cancer in the early stage;\n* women treated or who will undergo oncological treatment for early breast cancer;\n* demonstrate the absence of psychopathological features.\n* be willing and able to provide written informed consent\u002Fassent for the trial\n\nExclusion Criteria:\n\n* breast cancer patients who showed physical or psychological issues, as well as cognitive impairments that prohibited their participation in this type of study;\n* neurological or psychiatric disorders that may compromise the patients' ability to take part in the study.\n* Distant metastases from breast cancer or locally advanced\u002Funresectable disease\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial","ALL","18 Years",{"count":69,"type":70},180,"ESTIMATED","OBSERVATIONAL","Women diagnosed with early-stage breast cancer need to make a decision about the therapeutic treatment to undertake. Since multiple factors can influence this decision, it is necessary to develop a decision-making support tool to assist them in making this choice.\n\nMain Objective: To develop a decision-making support tool for determining the treatment to undertake for women diagnosed with early-stage breast cancer and test its effectiveness on an experimental group.",[74,75,76],"Breast Carcinoma","Breast Cancer Stage I","Breast Cancer Stage II",[78,79,80],"early breast cancer","Patient Decision","engagement","2025-11-21",{"date":83,"type":84},"2025-11-28","ACTUAL",{"date":86,"type":84},"2025-01-22",{"date":88,"type":70},"2027-01",{"name":5,"class":6},1]